Related Experiment Video
Updated: May 29, 2025

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases
Published on: October 10, 2020
Isozyme-specific inhibition of GSTP1-1: a crucial element in cancer-targeting drugs
Belal O Al-Najjar1, M Helal2, Fadi G Saqallah3
1Department of Pharmaceutical Sciences, Faculty of Pharmacy, Al-Ahliyya Amman University Amman 19328 Jordan b.najjar@ammanu.edu.jo.
Abstract:
Selectively targeting cancer cells has been a main challenge in cancer therapy. The purpose is to spare normal cells and minimize side effects. Targeting the antioxidant enzymes (i.e. GST) for the purpose of selectively killing cancer cells has attracted much attention in the past few decades. The intention of lowering the antioxidant enzymes is "tipping" the ROS concentrations to levels above the cytotoxic threshold. This would result in extensive damage to the cellular macromolecules and organelles leading to cell death. Here we focused on the glutathione S-transferase pi 1 (GSTP1), because it is one of the overexpressed antioxidant enzymes in cancer and has been targeted for the purpose of killing cancer cells. However, most available GSTP1 inhibitors do not show selectivity towards the isozyme. This can potentially lead to many side effects. Therefore, the search for optimal selective GSTP1 inhibitors is still underway. The novelty of this review stems from highlighting the significance of selectively targeting GSTP1. We also addressed the structural feature of the enzyme which challenges the design of novel selective GSTP1 inhibitors. We then provide guidelines to help resolve these challenges to help design future compounds. The first objective of this review is to present a brief literature review to highlight the importance of selectively targeting GSTP1. Briefly, the lack of selectivity towards GSTP1 has resulted in extensive side effects which limited reaching advanced clinical trials. We screened publications on many potential inhibitors, including some that reached phase I and II clinical trials, for their ability to bind with GSTP1, GSTM, and GSTA. All compounds appear to bind different GST isozymes (at least to some extent). The second objective is to present differences in the structures of GST isotypes (GSTP1, GSTM, GSTA) which could allow selectively targeting a certain isotype. Our modelling results highlight the importance of certain structural moieties for better selective binding to GSTP1.
Insights
Targeting cancer cells selectively is crucial for effective therapy. This review highlights the need for selective glutathione S-transferase pi 1 (GSTP1) inhibitors to minimize side effects and improve cancer treatment outcomes.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Therapy
Background:
- Selective cancer cell targeting remains a significant challenge in oncology.
- Antioxidant enzymes like glutathione S-transferases (GSTs) are overexpressed in cancer, making them therapeutic targets.
- Glutathione S-transferase pi 1 (GSTP1) is a key overexpressed enzyme, but existing inhibitors lack isozyme selectivity, causing side effects.
Purpose of the Study:
- To emphasize the critical importance of selectively targeting GSTP1 in cancer therapy.
- To explore structural features of GST isotypes that hinder selective inhibitor design.
- To provide guidelines for developing novel, selective GSTP1 inhibitors.
Main Methods:
- Literature review of GSTP1 inhibitors and their binding affinities across GST isotypes (GSTP1, GSTM, GSTA).
- Analysis of structural differences between GST isotypes.
- Computational modeling to identify structural moieties crucial for selective GSTP1 binding.
Main Results:
- Many potential GSTP1 inhibitors exhibit cross-isozyme binding, limiting clinical efficacy due to side effects.
- Structural variations among GST isotypes present opportunities for selective targeting.
- Modeling identified specific structural features important for achieving selective GSTP1 inhibition.
Conclusions:
- Selective GSTP1 inhibition is vital for effective and safe cancer therapy.
- Understanding GST isotype structural differences is key to designing potent and selective inhibitors.
- Further research into structural moieties can guide the development of next-generation GSTP1-targeted cancer drugs.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Inhibition of Cdk Activity
Drugs that Stabilize Microtubules
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

